PharmacyCodes



Buclizina [Inn-Spanish] en es it fr

Buclizina [Inn-Spanish] Brand names, Buclizina [Inn-Spanish] Analogs

Buclizina [Inn-Spanish] Brand Names Mixture

  • No information avaliable

Buclizina [Inn-Spanish] Chemical_Formula

C28H33ClN2

Buclizina [Inn-Spanish] RX_link

No information avaliable

Buclizina [Inn-Spanish] fda sheet

Buclizina [Inn-Spanish] msds (material safety sheet)

Buclizina [Inn-Spanish] Synthesis Reference

No information avaliable

Buclizina [Inn-Spanish] Molecular Weight

433.028 g/mol

Buclizina [Inn-Spanish] Melting Point

218 oC (BP)

Buclizina [Inn-Spanish] H2O Solubility

No information avaliable

Buclizina [Inn-Spanish] State

Liquid

Buclizina [Inn-Spanish] LogP

7.749

Buclizina [Inn-Spanish] Dosage Forms

Tablet (50 mg)

Buclizina [Inn-Spanish] Indication

For prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness and vertigo (dizziness caused by other medical problems).

Buclizina [Inn-Spanish] Pharmacology

Buclizine is a piperazine-derivative antihistamine used as an antivertigo/antiemetic agent. Buclizine is used in the prevention and treatment of nausea, vomiting, and dizziness associated with motion sickness. Additionally, it has been used in the management of vertigo in diseases affecting the vestibular apparatus. Although the mechanism by which buclizine exerts its antiemetic and antivertigo effects has not been fully elucidated, its central anticholinergic properties are partially responsible. The drug depresses labyrinth excitability and vestibular stimulation, and it may affect the medullary chemoreceptor trigger zone. It also possesses anticholinergic, antihistaminic, central nervous system depressant, and local anesthetic effects.

Buclizina [Inn-Spanish] Absorption

Rapidly absorbed following oral administration.

Buclizina [Inn-Spanish] side effects and Toxicity

No information avaliable

Buclizina [Inn-Spanish] Patient Information

Buclizina [Inn-Spanish] Organisms Affected

Humans and other mammals